QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.108.144121v1 328/2/579    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Bogulavsky, J. J. Articles by Inturrisi, C. E. Search for Related Content PubMed PubMed Citation Articles by Bogulavsky, J. J. Articles by Inturrisi, C. E. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB MORPHINE

NEUROPHARMACOLOGY

Deletion of the Glutamate Receptor 5 Subunit of Kainate Receptors Affects the Development of Morphine Tolerance

Departments of Neuroscience (J.J.B., C.E.I., A.M.R.), Pharmacology (A.M.G., P.T.-H.K., C.E.I.), and Pediatric Neurology, Pediatrics (A.M.R.), Weill Cornell Medical College, New York, New York; and Departments of Medicine and Psychiatry and Neuroscience Training Program (A.C.S.C.), University of Colorado at Denver and the Health Sciences Center, Denver, Colorado

Previous reports utilizing pharmacological antagonists implicate kainate receptor (KAR) activation in the development of morphine tolerance, dependence, conditioned place preference (CPP), and locomotor sensitization, but the role of glutamate receptor (GluR) 5-containing KAR in these effects remains unclear because of limited selectivity of the inhibitors employed. Therefore, we examined responses to systemic morphine treatment in mice expressing a constitutive deletion of GluR5 [GluR5 knockout (KO)]. Unlike wild-type (WT) littermates, GluR5 KO mice do not develop tolerance after repeated morphine administration by subcutaneous injection or via subcutaneous pellet implantation. In contrast, GluR5 KO mice do not differ from WT with respect to thermal or mechanical nociceptive thresholds, acute morphine antinociception, morphine disposition in the central nervous system (CNS), morphine physical dependence as revealed by naloxone-precipitated withdrawal or development of place preference and locomotor hyperresponsiveness after chronic morphine administration. It is surprising that continuous subcutaneous infusion of the GluR2/GluR5-preferring antagonist LY293558 [(3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid] decreased the number of naloxone-precipitated jumps to a similar extent in WT and GluR5 KO mice. We observed opioid-induced hypersensitivity in both groups during morphine withdrawal as demonstrated by equivalent reductions in thermal and mechanical thresholds; however, this hypersensitivity was not evident during continuous systemic morphine infusion. These data collectively indicate that KARs containing the GluR5 subunit contribute to the development of morphine tolerance without affecting nociceptive thresholds, morphine analgesia, or disposition in CNS of morphine and its metabolite morphine-3-glucuronide. In addition, constitutive deletion of GluR5 does not alter the morphine-induced increase in locomotor activity or the acquisition of morphine reward as measured by a CPP paradigm.

Address correspondence to: Dr. Charles E. Inturrisi, Department of Pharmacology, Weill Cornell Medical College, Room LC-524, 1300 York Avenue, New York, NY 10065. E-mail: ceintur{at}med.cornell.edu